The diet industry generates about $140–150 billion worldwide each year, with the U.S. near $90 billion recently.
If you’re asking “how much money does the diet industry make per year?”, the honest answer depends on scope. Most trackers bundle products, services, and prescription options under “weight management.” Using recent market studies, the global take sits near the mid-$100-billion mark, while the U.S. slice alone has surged toward $90 billion as new obesity drugs enter mainstream care. Below, you’ll see where that money comes from and why the totals vary by source.
How Much Money Does The Diet Industry Make Per Year? — Global Vs. U.S. Figures
There isn’t a single clearinghouse for diet revenue. Instead, analysts publish category snapshots with different cut lines. That’s why one report may tally supplements and services but skip prescription drugs, while another rolls them together under “weight management.” The first table compiles frequently cited figures and the year each was recorded so you can see the range at a glance.
Latest Credible Revenue Snapshots
| Category / Region (Year) | Revenue | Source |
|---|---|---|
| Weight management market, global (2022) | $142.6B | Grand View Research |
| Diet products segment, global (2022) | $108.8B | Grand View Research |
| Weight loss services, global (2023) | $36.3B | Grand View Research |
| Weight loss supplements, global (2024) | $33.1B | Grand View Research |
| GLP-1 weight loss drugs, global (2024) | $13.8B | Grand View Research |
| Total weight loss market, U.S. (2023) | $90B | Marketdata / Research & Markets |
| Weight loss services market, U.S. (2025) | $2.6B | IBISWorld |
Roll those pieces up and you get a working answer to “how much money does the diet industry make per year?”: roughly $140–150 billion worldwide in the early-to-mid 2020s, with the U.S. contributing a sizable share. The global figure stems from the broader weight management market, which includes foods, drinks, programs, digital tools, fitness tie-ins, and medical options.
What Drives The Money Flow
Three forces shape the revenue curve. First, consumer demand is persistent: many adults try weight control each year, and many buy help beyond home cooking and walking plans. Second, prescription GLP-1 options opened a new high-ticket lane that barely existed a few years ago. Third, business models are shifting—commercial programs are adding telehealth and clinician-guided plans to keep pace with medication-driven care.
The Role Of New Obesity Drugs
GLP-1–based therapies such as semaglutide and tirzepatide have sparked real spending. Independent reporting shows one manufacturer now posting quarterly revenues above ten billion dollars for this franchise, underscoring how fast dollars are moving toward prescription care. Research publishers that track the category estimate a mid-teens growth path through 2030 as access expands and supply stabilizes. That money flows through insurers, pharmacies, and direct cash-pay programs, and it’s reshaping budgets for both consumers and employers.
Behavior And Prevalence
Prevalence of obesity remains high across U.S. states, which keeps demand steady for weight management help. Public health tracking shows at least one in five adults with obesity in every state, and many states at one in three or more. Those rates help explain why diet spending stays elevated even when specific brands rise or fade.
Methods Behind The Numbers
To keep the estimates grounded, this piece triangulates between global market studies and U.S. status reports that include both commercial chains and medical channels. Figures are rounded and presented with the year of measurement so readers can gauge time gaps and momentum.
Scope Differences To Watch
When you scan any market chart, check what’s included. Some counts fold in meal-replacement shakes, subscription apps, prepared diet foods, and coaching. Others add prescription drugs only when they’re labeled for weight loss, not when they’re sold for diabetes at different doses. A few focus entirely on brick-and-mortar services. Those choices change the totals.
How Analysts Compile Revenue
Most firms use bottom-up models: company filings, channel checks, shipment data, and expert interviews. They map categories, apply price and volume assumptions, then reconcile against national accounts. Because inputs differ, reasonable studies can land on different totals. The goal here isn’t to crown a single number; it’s to give a clear, sourced range and explain the moving parts.
Practical Takeaways For Readers And Brands
For readers vetting plans, brand scale doesn’t guarantee fit or results. Safety, cost, and support matter. For operators, the spend is there, but the mix is changing. Coaching alone is under pressure; programs with medical oversight, long-term nutrition plans, and sustainable habits show better retention.
Costs You Can Expect
Spending levels vary. Prescription paths can run into the hundreds per month without coverage. Coaching plans and meal kits bundle fees into subscriptions. Over-the-counter supplements look cheaper per bottle but can add up across a year. Always check your insurer’s rules and any employer programs that offset costs.
Linked Data And Rules You Can Trust
Public health numbers help explain why demand is steady. See the CDC obesity prevalence maps for state-level trends. On the prescription side, read the FDA page on unapproved GLP-1 drugs to understand safety and quality concerns around non-approved versions. These two resources give a reliable backdrop for the spending figures above.
Is Growth Slowing Or Accelerating?
The top-line answer: global revenue is still climbing. A widely cited global baseline puts weight management near $143 billion in 2022 with a near-double projection by 2030. Within that, GLP-1 weight loss drugs are rising fast, while some commercial diet chains have seen revenue slip and are pivoting to medical care models. Even with churn at the brand level, category revenue has fresh tailwinds.
Forecasts At A Glance
| Category | 2030 Projection | Basis |
|---|---|---|
| Weight management market, global | $298.7B | Grand View Research |
| GLP-1 weight loss drugs, global | $48.8B | Grand View Research |
| Weight loss services, global | ~7.6% CAGR (’24–’30) | Grand View Research |
Breakdown: Where The Dollars Go
Drugs And Prescriptions
Insurer coverage varies by plan, and cash-pay demand remains strong. Pharmacies, clinic networks, and telehealth firms are building programs around dosing, nutrition, and side-effect management. As supply stabilizes, pricing and access may shift again.
Programs, Coaching, And Services
Traditional commercial chains still sell memberships, meal bundles, workshops, and one-to-one coaching. The U.S. services slice alone is measured in the low billions, a smaller piece of the total pie than headlines suggest, yet a durable one thanks to recurring fees and upsells.
Food, Drinks, And Supplements
Retail shelves carry shakes, bars, portion-controlled meals, and appetite aids. This cluster remains large worldwide and usually grows with household incomes and marketing pushes. It also behaves like fast-moving consumer goods: lots of brand switching, steady promotions, and strong private labels.
How To Read Market Claims Smartly
When a headline says the diet business is worth a certain number, ask three quick questions. What’s the year of the estimate? What’s in the basket—does it include prescriptions, services, and packaged foods, or only one piece? And is the figure global or U.S.-only? If you can answer those, you’ll parse most claims quickly.
What This Means If You’re Budgeting
Pick a plan you can fund for months, not days. Small monthly fees can add up; high drug costs can crowd out other health spending. Make a simple worksheet with recurring costs, check coverage, and be ready to adjust if your plan changes or a generic arrives.
Sources Used And How They Differ
Grand View Research publishes global totals for weight management, services, and supplements (2022–2024 snapshots, plus 2030 projections). IBISWorld lists U.S. services revenue and business counts (latest 2025 reading). Marketdata’s 2024 status report pegged the broader U.S. market at about $90 billion in 2023 during the obesity-drug surge. Trade press has documented how GLP-1 revenues now rival the biggest categories in pharma. The range you saw reflects those scopes.
The Bottom Line
On balance, the diet economy is big, and it’s growing. Using credible, recent baselines, worldwide revenue sits around the mid-$100-billion mark, with projections near $300 billion by decade’s end. In the U.S., total spending reached about $90 billion recently. Your best move is to filter claims by scope and year, then decide where your dollars deliver real value for your goals.